6533b820fe1ef96bd1279a96

RESEARCH PRODUCT

Patients' Acceptability of Different Fentanyl Products for Breakthrough Cancer Pain

Antonino TuttolomondoG. BellaviaSebastiano MercadanteAlessandra CasuccioAmanda CaruselliM.r. Meli

subject

Settore MED/06 - Oncologia Medicabusiness.industryBreakthrough PainBreakthrough PainPatient Acceptance of Health CareSettore MED/42 - Igiene Generale E ApplicatafentanylFentanylbreakthrough cancer painBTPOncologyNeoplasmsAnesthesiaAdministration MucosalHumansMedicineRadiology Nuclear Medicine and imagingpatient's preferencefentanyl; breakthrough cancer pain; BTP; patient's preferencebusinessCancer painmedicine.drug

description

OTFC (6) 1.7 (0.5) 1.5 (0.5) 2.0 (0.6) 1.5 (0.8) 1.5 (0.5) 33.1 (43.5) FBT (19) 2.0 (0.6) 2.0 (0.7) 1.8 (0.7) 1.8 (0.8) 1.9 (0.7) 15.9 (7.3) SLF (37) 2.1 (0.5) 2.2 (0.4) 1.8 (0.4) 2.0 (0.6) 2.1 (0.5) 16.7 (12.5) INFS (7) 2.1 (0.4) 2.1 (0.4) 2.0 (0.6) 2.0 (0.8) 2.0 (0.8) 15.7 (13.7) PFEN (11) 2.4 (0.5) 2.2 (0.4) 1.8 (0.4) 1.9 (0.7) 2.1 (0.5) 15.0 (13.7) P 0.120 0.043* 0.870 0.595 0.178 0.015x *,x Oral transmucosal fentanyl was significantly considered to be more problematic.

yearjournalcountryeditionlanguage
2014-01-01Clinical Oncology
https://doi.org/10.1016/j.clon.2014.09.003